Literature DB >> 27037297

Severe exacerbation or manifestation of primary disease related to nivolumab in non-small-cell lung cancer patients with poor performance status or brain metastases.

O Kanai1, K Fujita1, M Okamura1, K Nakatani1, T Mio2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27037297     DOI： 10.1093/annonc/mdw148

Source DB:  PubMed          Journal:  Ann Oncol        ISSN： 0923-7534            Impact factor:   32.976


× No keyword cloud information.
  13 in total

1.  Immediate Progressive Disease in Patients with Metastatic Renal Cell Carcinoma Treated with Nivolumab: a Multi-Institution Retrospective Study.

Authors:  Hiroki Ishihara; Tsunenori Kondo; Toshio Takagi; Hidekazu Tachibana; Hironori Fukuda; Kazuhiko Yoshida; Junpei Iizuka; Hirohito Kobayashi; Kazunari Tanabe
Journal:  Target Oncol       Date:  2018-10       Impact factor: 4.493

2.  Risk of tumor flare after nivolumab treatment in patients with irradiated field recurrence.

Authors:  Tatsuya Yoshida; Hiromi Furuta; Toyoaki Hida
Journal:  Med Oncol       Date:  2017-01-30       Impact factor: 3.064

3.  Rapid Progressive Disease After Nivolumab Therapy in Three Patients with Metastatic Renal Cell Carcinoma.

Authors:  Yuki Kobari; Tsunenori Kondo; Toshio Takagi; Kenji Omae; Hayakazu Nakazawa; Kazunari Tanabe
Journal:  In Vivo       Date:  2017 Jul-Aug       Impact factor: 2.155

4.  Imaging challenges of immunotherapy and targeted therapy in patients with brain metastases: response, progression, and pseudoprogression.

Authors:  Norbert Galldiks; Martin Kocher; Garry Ceccon; Jan-Michael Werner; Anna Brunn; Martina Deckert; Whitney B Pope; Riccardo Soffietti; Emilie Le Rhun; Michael Weller; Jörg C Tonn; Gereon R Fink; Karl-Josef Langen
Journal:  Neuro Oncol       Date:  2020-01-11       Impact factor: 12.300

Review 5.  Immune Checkpoint Inhibitors for Brain Metastases.

Authors:  Aaron C Tan; Amy B Heimberger; Alexander M Menzies; Nick Pavlakis; Mustafa Khasraw
Journal:  Curr Oncol Rep       Date:  2017-06       Impact factor: 5.075

6.  Immunotherapy for non-small cell lung cancer: from clinical trials to real-world practice.

Authors:  Sawsan Rashdan; David E Gerber
Journal:  Transl Lung Cancer Res       Date:  2019-06

Review 7.  Targeted therapies for the treatment of non-small-cell lung cancer: Monoclonal antibodies and biological inhibitors.

Authors:  Ana P S Silva; Priscila V Coelho; Maristella Anazetti; Patricia U Simioni
Journal:  Hum Vaccin Immunother       Date:  2016-11-10       Impact factor: 3.452

Review 8.  History and current state of immunotherapy in glioma and brain metastasis.

Authors:  Tresa McGranahan; Gordon Li; Seema Nagpal
Journal:  Ther Adv Med Oncol       Date:  2017-02-01       Impact factor: 8.168

9.  Partial response of pulmonary adenocarcinoma with symptomatic brain metastasis to nivolumab plus high-dose oral corticosteroid: a case report.

Authors:  Hélène Pluchart; Julian Pinsolle; Julien Cohen; Gilbert R Ferretti; Pierrick Bedouch; Matteo Giaj Levra; Anne-Claire Toffart; Denis Moro-Sibilot
Journal:  J Med Case Rep       Date:  2017-07-06

Review 10.  Management of brain metastases according to molecular subtypes.

Authors:  Riccardo Soffietti; Manmeet Ahluwalia; Nancy Lin; Roberta Rudà
Journal:  Nat Rev Neurol       Date:  2020-09-01       Impact factor: 42.937
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.